Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
SMIC Profits Soar to $138m in Second Quarter
Foldable Phone-Maker Plans Shenzhen IPO, Dispelling Rumors of U.S. Listing
Astra Inks Oxford Vaccine Production Deal with China’s Kangtai
Trending Story: Are Any New Graduates Really Worth 2 Million Yuan a Year? Netizens Discuss!
Trending in China: Popcorn or Cheaper Tickets - What Would Make You Return to the Cinema?
Tesla Challenger Xpeng Raises $400 Million Before Planned U.S. IPO
CATL Announces it Will Supply Batteries for Mercedes-Benz New Electric Sedan
TikTok Sees No Slowdown in Global Popularity Despite Indian Ban and U.S. Threats
Baidu Search, Sina Weibo on ‘Secret List’ of Chinese Apps Banned in India’s Latest Purge
Trending in China: Choosing a College Major - For Love or Money?
Evergrande Health Forges Ahead With Six New Electric Vehicles
Trending in China: How Cute Rabbit Ears Are On the Frontline in Fight Between Delivery Firms
Chinese Company Files Lawsuit Against Apple’s Siri for Patent Infringement Worth Billions
China Home to Six of the World’s Top 10 Unicorns, Hurun Report Says
Trending in China: Can Music Streamers Help Users’ Depression?
Core Parts of China’s Beidou Satellite System ‘100% Made in China’
Trending in China: Xiaomi CEO’s Shows How Best To Harness China’s Social Media Humor for Serious Business
Apple Takes Down Over 30,000 Apps from China Store Amid Government Crackdown
Chinese Chipmaker SMIC to Establish Joint Venture for Wafer Production
Microsoft Said Plan to Acquire TikTok Will Continue
German Drugmaker BI Launches Shanghai Center to Harness Chinese Expertise

By Ding Yi / Jul 03, 2020 04:35 PM / Business & Tech

Photo: Visual China

Photo: Visual China

German pharmaceutical firm Boehringer Ingelheim (BI) has launched its External Innovation Hub in Shanghai in a bid to harness China’s expertise in life science innovation to power its global drug discovery and development chain.

A big feature of the hub is that the facility adopts a so-called “3-in-1” system, meaning that it will integrate BI’s external-facing functions including Research Beyond Borders (RBB), Business Development & Licensing (BD&L) and BI Venture Fund (BIVF) under one roof, according to a statement by the company Thursday.

RBB is a global research unit BI likens to a “radar” that can detect the next big wave of innovation in life science. The BD&L team and the BIVF together play a role in turning scientific approaches into business ideas.

The hub will also create various partnerships to help BI sharpen its core therapeutic capabilities, meet urgent medical needs and possibly identify therapeutic areas for future strategic investment.

The launch of the Shanghai hub comes three months after BI unveiled a plan to open a digital lab in July in the same city, with plans to recruit dozens of experts in digital healthcare to help develop medicines and therapies for the Chinese market.

In a separate post published on its public WeChat account, BI said that it plans to invest 451 million euros ($508 million) over the next five years in China, a market it entered more than two decades ago.

Since its entry into China, BI has forged partnerships with multiple local academic institutions and companies in the country including Tsinghua University and Peking University, the company said.

In recent years, foreign drugmakers have increased investment in China, where the government aims to grow the healthcare industry to 8 trillion yuan ($1.1 trillion) by the end of 2020 and 16 trillion yuan by 2030

Contact reporter Ding Yi (yiding@caixin.com)

Related: German Drugmaker BI to Establish Digital Lab in Shanghai


Share this article
Open WeChat and scan the QR code